Expert Interview
A Second Opinion: Discussing the standard of care and the potential of 4D-150, a novel genetic medicine that utilizes 4DMT’s evolved and customized R100 vector for intravitreal delivery to the retina to treat wet AMD.
Ticker(s): FDMTInstitution: Duke Eye Center
- Ophthalmologist and Medical Director of the Retina Injection clinic at Duke Eye Center.
- Currently manages around 360 patients with wet AMD and very familiar with the recent ARVO conference from the Phase 1/2 PRISM trial of 4D-150 in wet AMD.
- Research focus on age-related macular degeneration (dry and wet AMD), diabeticretinopathy, diabetic macular edema, retinal vascular diseases, and other macular andretinal diseases.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
